Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 1 AL 15

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R.

Curr Drug Targets. 2017;18(2):174-195. doi: 10.2174/1389450116666150825113655.

CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease

Ambure P, Roy K.

Curr Drug Targets. 2017;18(5):522-533. doi: 10.2174/1389450116666150907104855.

Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease

Russo P, Kisialiou A, Moroni R, Prinzi G, Fini M.

Curr Drug Targets. 2017;18(10):1179-1190. doi: 10.2174/1389450116666151001111826.

Multi-Target Mining of Alzheimer Disease Proteome with Hansch's QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline

Abeijon P, Garcia-Mera X, Caamano O, Yanez M, Lopez-Castro E, Romero-Duran FJ, Gonzalez-Diaz H.

Curr Drug Targets. 2017;18(5):511-521. doi: 10.2174/1389450116666151102095243.

Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE

Koster KP, Smith C, Valencia-Olvera AC, Thatcher GR, Tai LM, LaDu MJ.

Curr Top Med Chem. 2017;17(6):708-720. doi: 10.2174/1568026616666160617090227.

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease

Karl T, Garner B, Cheng D.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160. doi: 10.1097/FBP.0000000000000247.

Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis

Bortolotto V, Grilli M.

CNS Neurol Disord Drug Targets. 2017;16(10):1066-1079. doi: 10.2174/1871527315666160803153459.

α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer`s Disease

Ma K, McLaurin J.

Curr Alzheimer Res. 2017;14(1):18-29. doi: 10.2174/1567205013666160819130641.

GABAergic Microcircuits in Alzheimer's Disease Models

Villette V, Dutar P.

Curr Alzheimer Res. 2017;14(1):30-39. doi: 10.2174/1567205013666160819125757.

Alzheimer's Drug Discovery Maze: A Snap View of the Past Decade's Diverse Pharmacological Targets for the Disorder

Sikazwe D, Yendapally R, Ramsinghani S, Khan M.

Mini Rev Med Chem. 2017;17(3):305-318. doi: 10.2174/1389557516666160822152625.

Role of Glutamate and NMDA Receptors in Alzheimer's Disease

Wang R, Reddy PH.

J Alzheimers Dis. 2017;57(4):1041-1048. doi: 10.3233/JAD-160763.

Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease

Michalska P, Buendia I, Del Barrio L, Leon R.

Curr Top Med Chem. 2017;17(9):1027-1043. doi: 10.2174/1568026616666160927154116.

Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer's Disease

Spilovska K, Korabecny J, Nepovimova E, Dolezal R, Mezeiova E, Soukup O, Kuca K.

Curr Top Med Chem. 2017;17(9):1006-1026. doi: 10.2174/1568026605666160927152728.

Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease

Decourt B, Lahiri DK, Sabbagh MN.

Curr Alzheimer Res. 2017;14(4):412-425. doi: 10.2174/1567205013666160930110551.

Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease

Farhat SM, Ahmed T.

Curr Drug Targets. 2017;18(13):1537-1544. doi: 10.2174/1389450117666161005145143.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias